GMU’s Reverse-phase Protein Microarray Technology Included in I-SPY2 Breast Cancer Trial
March 26, 2010
GMU’s Reverse-phase Protein Microarray Technology Included in I-SPY2 Breast Cancer Trial
Technology developed by Lance Liotta and Emanuel Petricoin will be used to find and identify biomarkers for evaluating new investigational therapies for the neoadjuvant-drug study.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- People In the News
October 15, 2010 / GenomeWeb Daily News - TARC Team Uses RBM's DiscoveryMAP Platform to Develop Alzheimer's Protein-Biomarker Test
September 17, 2010 / ProteoMonitor - Bio-Rad Develops More Sensitive, Streamlined Workflow for SPR-Mass Spec
August 26, 2011 / ProteoMonitor - Funding Update
August 26, 2011 / ProteoMonitor - Proteomics Technologies Making Their Way into Pathogen Detection
August 19, 2011 / ProteoMonitor